The Maharashtra Food and Drug Administration (FDA) has seized drugs worth Rs.75,000 from Mumbai-based pharmaceutical distributor Kailash Pharma for illegal stock and sale of products sold as vitamins and calcium under the brand name Calcimax 500 manufactured originally by Meyer Organics Pvt. Ltd. The spurious product was purchased from Vapi based wholesaler and sold in retail chain in an illegal way.
“Same product worth Rs.20,000 have also been recalled and seized in the interest of patient safety. Maharashtra FDA has lodged an FIR in this case at Kalachowki Police Station and investigations are on to get more details about the clandestine operations in the way the drugs were circulated and name of the companies involved,”informed Drug Inspector KG Gadewar.
The offenders have been booked under Drugs and Cosmetics Act in violation of Section 17 b, 18 (a) (i) and Section 27 c of the Indian Penal Code (IPC).
“Initial investigations have revealed that the manufacturer is based in Dehradun who used to manufacture the product for Mumbai based Meyer Organics,” Gadewar added.
Meyer Organics is one of the leading pharmaceutical manufacturers in India, founded in 1982 in technical collaboration with OMEGA – MEYER Ltd. Headquartered in Mumbai, India with global presence in more than 30 countries, Meyer manufactures innovative healthcare products for over two decades. Meyer is committed to excel in human healthcare and research. Meyer has created a unique portfolio of products in the key segments like anti-infective, nutrition supplements for all age groups, infertility supplement, pain management, etc.
The state drug regulator collected 2,760 drug samples and found 205 not-of-standard quality (NSQ) drugs in the state through its routine inspections over the past six months. Out of the samples collected, 317 samples drawn were of cosmetic products.
Complete drug recall of NSQ drugs is the major objective of the inspections conducted across the manufacturing units, retail supply chain and wholesalers.
Centre has already sanctioned Rs.138 crore for strengthening drug regulatory system in the state. Funds to the tune of Rs.17 crore has been allocated for the Nagpur project for strengthening labs and manpower.
To enhance testing capacities, Maharashtra FDA will soon set up a National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited drug testing lab in Nagpur. A microbiological testing lab is also being planned at the Mumbai FDA headquarters.
“Same product worth Rs.20,000 have also been recalled and seized in the interest of patient safety. Maharashtra FDA has lodged an FIR in this case at Kalachowki Police Station and investigations are on to get more details about the clandestine operations in the way the drugs were circulated and name of the companies involved,”informed Drug Inspector KG Gadewar.
The offenders have been booked under Drugs and Cosmetics Act in violation of Section 17 b, 18 (a) (i) and Section 27 c of the Indian Penal Code (IPC).
“Initial investigations have revealed that the manufacturer is based in Dehradun who used to manufacture the product for Mumbai based Meyer Organics,” Gadewar added.
Meyer Organics is one of the leading pharmaceutical manufacturers in India, founded in 1982 in technical collaboration with OMEGA – MEYER Ltd. Headquartered in Mumbai, India with global presence in more than 30 countries, Meyer manufactures innovative healthcare products for over two decades. Meyer is committed to excel in human healthcare and research. Meyer has created a unique portfolio of products in the key segments like anti-infective, nutrition supplements for all age groups, infertility supplement, pain management, etc.
The state drug regulator collected 2,760 drug samples and found 205 not-of-standard quality (NSQ) drugs in the state through its routine inspections over the past six months. Out of the samples collected, 317 samples drawn were of cosmetic products.
Complete drug recall of NSQ drugs is the major objective of the inspections conducted across the manufacturing units, retail supply chain and wholesalers.
Centre has already sanctioned Rs.138 crore for strengthening drug regulatory system in the state. Funds to the tune of Rs.17 crore has been allocated for the Nagpur project for strengthening labs and manpower.
To enhance testing capacities, Maharashtra FDA will soon set up a National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited drug testing lab in Nagpur. A microbiological testing lab is also being planned at the Mumbai FDA headquarters.